ConclusionsThe comparison of real-life patients' characteristics with regulatory trials, displayed several apparent discrepancies. The demographic and clinical aspects were similar in all groups, whereas other features (eosinophil count, pulmonary function FEV1%) differed. These data, for the first time, could represent a basis for a more accurate prescription of the drug. (Source: World Allergy Organization Journal)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2E5qzzH
Τετάρτη 5 Δεκεμβρίου 2018
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.